Archive · 23 Jan 2026
Dr Reddy's Labs Shares Rise 5% After Q3 Earnings
Dr Reddy's Laboratories, a big pharmaceutical company, released its earnings for the third quarter of 2025.
Their stock price went up by 5% because even though their profit went down by 14%, their overall revenue went up by 4.4%.
The company did really well in India, where their revenue grew by 19%, and in Europe, where it grew by 20%.
They also have some exciting new products coming out, like a Semaglutide injection in India and a new drug collaboration.
Additionally, they plan to launch a generic version of Ozempic in India at a competitive price starting March 2025.
They are preparing to make 12 million pens in the first year and are also working on getting approval for a weight-loss drug in Canada.
A financial expert thinks the stock could go even higher, to Rs 1,545.
Dr Reddy's Laboratories shares surged 4.82% to Rs 1,211.20 after Q3 earnings.
Consolidated net profit declined 14% to Rs 1,209.8 crore due to higher expenses and North American challenges.
Consolidated revenue increased 4.4% to Rs 8,726.8 crore.
India revenue grew 19% YoY to Rs 1,603 crore, and European revenue grew 20% YoY to Rs 1,448 crore.
Company received marketing authorization for Semaglutide injection in India and plans to launch generic Ozempic in March 2025.
- Who
- Dr Reddy's Laboratories
- What
- Reported Q3 earnings, shares rose 5%, and plans to launch generic Ozempic in India
- When
- Third quarter ended December 31, 2025; Ozempic launch planned for March 2025
- Where
- India, US, Europe, Emerging Markets, Canada
- Why
- Strong domestic and European growth, strategic collaborations, and competitive pricing for generic Ozempic
Positive Outlook
Challenges Ahead
Financial Performance
Positive Outlook
Strong revenue growth of 4.4% and significant increases in India and Europe markets.
Challenges Ahead
Net profit declined by 14% due to higher expenses and challenges in North America.
Market Strategy
Positive Outlook
Competitive pricing for generic Ozempic to ensure affordability and market capture.
Challenges Ahead
Facing regulatory hurdles in Canada and awaiting approval for Wegovy.
- Stock Price Increase
- 4.82% to Rs 1,211.20
- Net Profit Decline
- 14% to Rs 1,209.8 crore
- Revenue Increase
- 4.4% to Rs 8,726.8 crore
- India Revenue Growth
- 19% YoY to Rs 1,603 crore
- European Revenue Growth
- 20% YoY to Rs 1,448 crore
- Emerging Markets Growth
- 32% YoY, with Russia up 51%
- Target Price
- Rs 1,545 (JM Financial)
- Generic Ozempic Launch
- March 2025, priced competitively
- Production Capacity
- 12 million pens in the first year
- Regulatory Status in Canada
- Awaiting response by May 2025
Sources
Dr Reddy's Labs shares jump 5% after Q3 earnings; target price, domestic growth & more
Dr Reddy's profit down 14% on low Lenalidomide US sales
Dr Reddy’s to start selling generic Ozempic in India from March at ‘competitive’ price
Dr Reddy’s lines up biosimilars and GLP 1 launches to counter slowdown in US business
Dr Reddy’s to launch generic Ozempic in India from March
